A carregar...
Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
A subset of non-small cell lung cancer (NSCLC) tumors (5%) harbors an anaplastic lymphoma kinase (ALK) translocation that drives tumorigenesis. The clinically approved first-line treatment crizotinib specifically inhibits ALK and improves progression-free survival (PFS) in treated and untreated pati...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5602476/ https://ncbi.nlm.nih.gov/pubmed/28979145 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S109493 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|